Xcout IntelOnKure Therapeutics, Inc.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Subscribe to see OnKure Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OnKure Therapeutics, Inc. at a glance
OnKure Therapeutics, Inc. is a biotech company headquartered in Boulder, United States. It is publicly listed (OKUR) with a market capitalisation of $88.1M. Xcout tracks 26 named people at OnKure Therapeutics, Inc., including Nicholas A. Saccomano (President, Chief Executive Officer & Director).
OnKure Therapeutics, Inc. leadership
- Nicholas A. SaccomanoPresident, Chief Executive Officer & Director
- Jason A. LeveroneChief Financial Officer
- Jason LeveroneChief Financial Officer
- Samuel AgrestaChief Medical Officer
- Dylan HartleyChief Scientific Officer
- James BlakeSenior Vice President of Computational Drug Discovery
20 more named people on record for OnKure Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
OnKure Therapeutics, Inc. competitors
A few of OnKure Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
OncoRock Therapeutics Inc. is a corporation located in Little Rock, Arkansas. The company operates in the life sciences sector, focusing on the research and development of oncology therapeutics.
Oncoinvent ASA is a biopharmaceutical firm dedicated to creating novel therapies for cancer. The company concentrates its efforts on building a diverse range of AXL kinase inhibitors. Its flagship product, bemcentinib, stands out as a highly selective, orally administered small molecule designed to inhibit AXL. James Bradley Lorens and David R. Micklem established the company on December 21, 2007, and it is based in Bergen, Norway.
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
IconOVir Bio, Inc. is a preclinical-stage biotechnology company headquartered in New York, United States, with a primary location in San Diego, California. Established in 2020, the venture-backed company is dedicated to pioneering novel oncolytic viral therapies to cure cancer and restore life to patients.
Get OnKure Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on OnKure Therapeutics, Inc. in Xcout Intel
- 26 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access